The estimated Net Worth of John P. Saharek is at least $11.5 million dollars as of 1 March 2024. Mr. Saharek owns over 5,000 units of Harrow Health stock worth over $10,541,200 and over the last 9 years he sold HROW stock worth over $0. In addition, he makes $963,798 as President of ImprimisRx at Harrow Health.
John has made over 6 trades of the Harrow Health stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of HROW stock worth $43,750 on 1 March 2024.
The largest trade he's ever made was exercising 277,200 units of Harrow Health stock on 18 July 2023 worth over $11,467,764. On average, John trades about 32,678 units every 171 days since 2016. As of 1 March 2024 he still owns at least 254,803 units of Harrow Health stock.
You can see the complete history of Mr. Saharek stock trades at the bottom of the page.
John P. Saharek is a President of ImprimisRx of the Company. Prior to his promotion to President of ImprimisRx in February 2019, Mr. Saharek served as the Company’s Chief Commercial Officer since February 2015 and its Vice-President of Commercialization, Ophthalmology since November 2012. He is a senior healthcare industry executive with over 30 years of broad experience developing and commercializing pharmaceutical, biotech, surgical device and diagnostic product portfolios. Prior to joining the Company, he served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercial strategy and building a team to launch a new biologic into the U.S. market. Prior to that he was Vice President, Business Development at SurModics Inc., working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives in the U.S. and internationally. Earlier in his career, he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Masters of Business Administration from the University of Hartford and a Bachelor’s degree from Central Connecticut State University.
As the President of ImprimisRx of Harrow Health, the total compensation of John Saharek at Harrow Health is $963,798. There are 2 executives at Harrow Health getting paid more, with Mark Baum having the highest compensation of $1,377,010.
John Saharek is 60, he's been the President of ImprimisRx of Harrow Health since 2019. There are 4 older and 7 younger executives at Harrow Health. The oldest executive at Harrow Health, Inc. is Dr. Robert J. Kammer D.D.S., 72, who is the Special Advisor.
John's mailing address filed with the SEC is 12264 El Camino Real #350, San Diego, CA 92130, USA.
Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum et Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Harrow Health executives and other stock owners filed with the SEC include: